Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

102.63 -2.64 (-2.51%)
Official Closing Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
Analysts expect Novo Nordisk's Ozempic and other major drugs to be included in 2027 Medicare price negotiations. Despite concerns, experts predict limited financial impact on companies like Pfizer,... 
Via Benzinga
RedHill's Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results
RedHill's Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results 
Via News Direct
These Were the Top-Selling GLP-1 Drugs Last Quarter From Eli Lilly and Novo Nordisk
Ozempic remains on top in the GLP-1 drug market -- but for how long? 
Via The Motley Fool
Forget Novo Nordisk: Buy This Magnificent Pharma Stock Instead
Vertex Pharmaceuticals has a lot going for it. 
Via The Motley Fool
What the Options Market Tells Us About Novo Nordisk
Via Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $5,900 Today
Via Benzinga
A Glimpse Into The Expert Outlook On Novo Nordisk Through 8 Analysts
Via Benzinga
Unpacking the Latest Options Trading Trends in Novo Nordisk
Via Benzinga
Wegovy Now Available Through Sesame's $249 Monthly Compounded Program Despite Supply Shortages
Sesame introduces an affordable weight loss program with compounded versions of Wegovy amid supply shortages. The program provides a $249 monthly alternative to expensive obesity treatments. 
Via Benzinga
Novo Nordisk Vs. Eli Lilly: Beyond The Weight-Loss Drug Battle
Novo Nordisk and Eli Lilly are competing for the obesity-drug market, but their growth plans extend beyond weight-loss treatments. They face supply chain challenges, but both stocks show strong bullish... 
Via Benzinga
Topics Economy
Exposures Supply Chain
Eli Lilly Stock Could Soar to $1,150, According to a Wall Street Analyst. Is It a Buy at Around $945?
The Big Pharma stock is up by more than 50% in 2024, but investment-bank analysts think it has more room to run. 
Via The Motley Fool
Ozempic And Wegovy Linked to Increased Suicidal Thoughts In Observational Study, But Results Are Contested
A recent study in JAMA Network Open raises concerns about a potential link between GLP-1 drugs Ozempic and Wegovy and an increased rate of suicidal thoughts after analyzing World Health Organization... 
Via Benzinga
Soviet Code Breaker Jim Simons' Hedge Fund Renaissance Technologies — Ozempic, Wegovy Maker Novo Nordisk Along With Nvidia, Palantir Among Top Holdings
Renaissance Technologies, the hedge fund founded by legendary mathematician and former NSA code breaker Jim Simons, recently disclosed its latest stock holdings in a 13F filing with the U.S. Securities... 
Via Benzinga
Telehealth Firm Hims & Hers Health Rides High On Demand for Copycat Weight Loss Drugs Amid Supply Shortages
Hims & Hers Health has seen its stock rise over 120% due to soaring demand for its affordable compounded GLP-1 weight-loss drugs, despite legal battles and safety concerns surrounding its... 
Via Benzinga
Prediction: These 2 Unstoppable Pharma Stocks Will Continue to Soar Through 2025 and Beyond
Impediments to growth are melting away while new opportunities begin to rise. 
Via The Motley Fool
Forget Mounjaro: Eli Lilly's Next Big Blockbuster Has Arrived
Eli Lilly has a lot going for it. 
Via The Motley Fool
Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years
Should Novo Nordisk and Eli Lilly investors be worried about Roche? 
Via The Motley Fool
These 3 Healthcare Companies Had the Top-Selling Drugs Last Year
This list of top-selling drugs could look drastically different in a few years. 
Via The Motley Fool
Is Madrigal Pharmaceuticals Stock a Buy?
The biotech could be worth a lot more in 10 years. 
Via The Motley Fool
3 Fantastic Growth Stocks to Buy in August
These stocks should keep up their winning ways. 
Via The Motley Fool
Could Viking Therapeutics Become the Next Novo Nordisk?
Given this biotech's ascent, its odds of becoming a giant are better than most. 
Via The Motley Fool
Doctors Struggle to Secure Medicare Coverage for Heart Patients on Novo Nordisk's Wegovy
Medicare patients struggle to access Novo Nordisk's Wegovy for heart disease treatment despite new guidelines, with many plans still denying coverage, highlighting challenges in the U.S. healthcare... 
Via Benzinga
Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming Market
Roche missed out on acquiring a potential blockbuster weight-loss drug, now owned by Eli Lilly, in 2018. The drug, orforglipron, is projected to generate up to $14 billion annually by 2032, while... 
Via Benzinga
Prediction: Up 74% So Far This Year, This Weight Loss Stock Is About to Crater
A small telemedicine company just entered the weight loss race. 
Via The Motley Fool
Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer)
There are a number of pharmaceutical companies looking to make waves in the weight loss market. 
Via The Motley Fool
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
The unveiled prices follow months of back-and-forth negotiation between the government and the companies. 
Via Investor's Business Daily
Is Novo Nordisk's Earnings Miss a Cause for Concern for Investors?
Novo Nordisk still expects to see a lot more growth in the second half. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Don't Promote Copycat Weight-Loss Drugs Amid Improved Supply, Eli Lilly Asks Doctors, FDA Evaluates
Eli Lilly issues cease-and-desist letters to healthcare providers, demanding they stop promoting compounded weight-loss drugs as supply improves. The move has sparked tension, with providers arguing... 
Via Benzinga
Exposures Product Safety
Eli Lilly Smashed Estimates Thanks To Unbelievable Demand For Its Diabetes And Weight Loss Blockbusters
On Thursday, Eli Lilly and Company (NYSE: LLY) reported its second quarter results, smashing estimates fueled by the popularity of its blockbuster diabetes drug Mounjaro and weight loss injection... 
Via Benzinga
3 Stable Blue-Chip Stocks to Buy for the Market Storm
Looking to shield your assets and protect your portfolio amid the current market volatility? Take refuge in these reliable stocks. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback